Skip to main content
Therma Bright Inc. logo

Therma Bright Inc. — Investor Relations & Filings

Ticker · THRM ISIN · CA8834262070 LEI · 529900PN7P0GSORO2174 TSXV Manufacturing
Open in API
Filings indexed 525 across all filing types
Latest filing 2022-12-21 Capital/Financing Update
Country CA Canada
Listing TSXV THRM

About Therma Bright Inc.

https://www.thermabright.com/

Therma Bright Inc. is a medical technology company that develops, acquires, and markets proprietary diagnostic and medical device technologies for the consumer and institutional healthcare sectors. The company's portfolio addresses key areas including pain management, circulation, diagnostics, and critical care. Core products and development projects include Venowave, a medical device designed to boost circulation and prevent blood clots; the Digital Cough Test (DCT), an AI-powered application developed with AI4LYF for rapid, non-invasive detection of respiratory diseases; and the PREVA™ clot retriever, developed with Inretio for enhanced thrombectomy procedures in ischemic stroke treatment. Furthermore, Therma Bright is advancing inhaled statin therapy in partnership with InVixa for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS).

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release dated December 21, 2022, providing a year-end update on Therma Bright Inc.'s activities and accomplishments during 2022. It discusses product development, regulatory status, market opportunities, partnerships, and future plans. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or quarterly reports. The content is a summary update rather than a formal financial report or regulatory filing. It is not a call transcript, audit report, or management report. The document is a corporate update announcement to shareholders and the public about business progress and outlook, typical of a capital/financing update or business progress update. Given the focus on business activities, regulatory progress, and market development rather than financial results, the best fitting category is Capital/Financing Update (CAP). The document length (10,475 characters) supports it being a substantive update rather than a brief announcement. Confidence is high due to clear content focus on business and regulatory progress rather than financial reporting.
2022-12-21 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Therma Bright Inc.'s investment and acquisition agreement related to novel treatments for COVID-19, asthma, and COPD. It details the terms of the acquisition, the companies involved, the technology, and forward-looking statements. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a regulatory filing. It is an announcement of a capital investment and financing transaction involving share issuance and strategic agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing transaction, not just a brief mention or a report publication announcement.
2022-12-01 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2022-11-29 English
Annual MD&A - English.pdf
Regulatory Filings
2022-11-29 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2022-11-29 English
Material change report - English.pdf
Regulatory Filings
2022-11-18 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.